As interim chief financial officer (CFO), Mark Renze oversees Prime Therapeutics (Prime) finance functions, including treasury and internal audit, real estate, financial planning and analysis, and the controller functions.

In addition to assuming the CFO roles, Renze continues to serve as vice president, financial planning and analysis. In this role, Renze oversees enterprise financial planning, budgeting, forecasting and reporting.

Renze joined Prime in 2008 and has successfully led finance and operations functions. He has proven effective in strategy building, pricing and benefit design, leading teams, collaborating with internal and external partners, negotiating contracts and utilizing digital systems to optimize outcomes. Prior to Prime, Renze spent 10 years at Thomson Reuters, serving in leadership positions in finance, IT and operations. Earlier, he worked in accounting and finance at Caterpillar Inc.

Renze earned a Bachelor of Business Administration degree from Iowa State University and a Master of Business Administration from Middle Tennessee State University.

Loading …